Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.6 USD | +1.42% | +13.68% | -22.60% |
Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Financials (USD)
Sales 2024 * | 50.25M | Sales 2025 * | 52.42M | Capitalization | 2.28B |
---|---|---|---|---|---|
Net income 2024 * | -512M | Net income 2025 * | -523M | EV / Sales 2024 * | 31 x |
Net cash position 2024 * | 717M | Net cash position 2025 * | 991M | EV / Sales 2025 * | 24.5 x |
P/E ratio 2024 * |
-4.27
x | P/E ratio 2025 * |
-4.45
x | Employees | 526 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.91% |
Latest transcript on Intellia Therapeutics, Inc.
1 day | +1.42% | ||
1 week | +13.68% | ||
Current month | +10.28% | ||
1 month | -5.49% | ||
3 months | -6.68% | ||
6 months | -17.94% | ||
Current year | -22.60% |
Managers | Title | Age | Since |
---|---|---|---|
John Leonard
CEO | Chief Executive Officer | 66 | 14-06-30 |
Glenn Goddard
DFI | Director of Finance/CFO | 53 | 18-10-28 |
Eliana Clark
CTO | Chief Tech/Sci/R&D Officer | 67 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Cohen
BRD | Director/Board Member | 67 | 19-01-23 |
John Leonard
CEO | Chief Executive Officer | 66 | 14-06-30 |
Frank Verwiel
CHM | Chairman | 62 | 17-07-23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.15% | 2 M€ | -25.75% | ||
4.87% | 1 M€ | 0.00% | - | |
4.17% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 23.6 | +1.42% | 1,294,988 |
24-05-02 | 23.27 | +3.42% | 1,218,715 |
24-05-01 | 22.5 | +5.14% | 1,686,447 |
24-04-30 | 21.4 | -2.64% | 1,201,235 |
24-04-29 | 21.98 | +5.88% | 1,325,645 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.60% | 2.28B | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- NTLA Stock